Rallybio, a biopharma company based in Connecticut, has raised $145m in a Series B financing round led by Pivotal bioVenture Partners, for developing therapies for severe and rare disorders.
Boehringer Ingelheim and CDR-Life announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA).
Catalent has collaborated with speciality pharmaceutical company Ennaid Therapeutics for the development of an oral and antiviral treatment for Covid-19 disease.
Moderna has secured fast track designation from the US Food and Drug Administration (FDA) for its mRNA-1273, the mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2).
Acer Therapeutics has joined forces with the US National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for Covid-19 patients.
JCyte has signed an ex-US licensing deal with Japanese ophthalmic company Santen Pharmaceutical worth up to $252m to develop and commercialise its investigational jCell therapy for a rare genetic eye disorder called retinitis pigmentosa.
Certara, the global leader in model-informed drug development, and DMTC (formerly the Defence Materials Technology Centre) Ltd, which works to enhance Australia’s defense and medical countermeasure capabilities, have entered into a research collaboration to evaluate the preventative use of chloroquine in health care workers at risk of infection from the novel coronavirus strain that causes Covid-19.
ZYUS Life Sciences has collaborated with University of Saskatchewan’s Vaccine and Infectious Disease Organisation-International Vaccine Centre (VIDO-InterVac) for the development of a plant-based vaccine for Covid-19 disease.
Twist Bioscience reported it has identified competitive antibodies to SARS-CoV-2, the virus that causes COVID-19, which could potentially be used for diagnostic tests or therapeutic treatments. Twist’s unique monoclonal antibody candidates bind with high affinity to the receptor binding domain (RBD) on the S1 spike protein on the surface of SARS-CoV-2 viral molecules.
Lineage Cell Therapeutics, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced that it has applied for grant funding from the California Institute for Regenerative Medicine (CIRM) to support the use of VAC, Lineage’s allogeneic dendritic cell therapy, toward the development of a potential vaccine against SARS-CoV-2, the virus which causes COVID-19.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.